title: Targeted antiestrogens for the prevention of breast cancer.
abstract: This commentary explores the recent experience with and the basis for the use of selective estrogen receptor modulators (SERMs) to prevent breast cancer. Chemoprevention has been a goal for many years. As newer agents are unveiled, they will continue to be tested against tamoxifen, the current standard for the treatment and prevention of breast cancer. Raloxifene holds the promise of treating osteoporosis with the beneficial side effect of breast cancer prevention. The Study of Tamoxifen and Raloxifene (STAR) trial and prior prevention studies will be discussed in an attempt understand the bridge from the laboratory to the clinic.
authors.affiliation: Department of Surgery, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Medical School, Chicago, IL 60611, USA.
authors.forename: D J
authors.initials: DJ
authors.lastname: Bentrem
authors.forename: V C
authors.initials: VC
authors.lastname: Jordan
mesh_terms: D001943:Breast Neoplasms / Q000378:metabolism / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D020847:Estrogen Receptor Modulators / Q000627:therapeutic use*; D005260:Female; D005544:Forecasting; D006801:Humans; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use*; D011960:Receptors, Estrogen / Q000378:metabolism; D013629:Tamoxifen / Q000627:therapeutic use*
chemical_list: D020847:Estrogen Receptor Modulators; D011960:Receptors, Estrogen; D013629:Tamoxifen; D020849:Raloxifene Hydrochloride